Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Medicinova (MNOV) EBITDA (2021 - 2025)

Medicinova (MNOV) has disclosed EBITDA for 7 consecutive years, with -$3.7 million as the latest value for Q4 2025.

  • On a quarterly basis, EBITDA changed N/A to -$3.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$13.6 million, a N/A change, with the full-year FY2025 number at -$12.0 million, down 8.34% from a year prior.
  • EBITDA was -$3.7 million for Q4 2025 at Medicinova, down from -$3.4 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$194620.0 in Q1 2021 to a low of -$4.3 million in Q2 2021.
  • A 5-year average of -$2.9 million and a median of -$3.1 million in 2023 define the central range for EBITDA.
  • Peak YoY movement for EBITDA: crashed 1643.84% in 2022, then surged 68.65% in 2023.
  • Medicinova's EBITDA stood at -$2.1 million in 2021, then plummeted by 75.28% to -$3.7 million in 2022, then soared by 43.87% to -$2.1 million in 2023, then decreased by 2.42% to -$2.1 million in 2024, then plummeted by 78.28% to -$3.7 million in 2025.
  • Per Business Quant, the three most recent readings for MNOV's EBITDA are -$3.7 million (Q4 2025), -$3.4 million (Q3 2025), and -$3.6 million (Q2 2025).